CureGN Study Rationale, Design, and Methods: Establishing a Large Prospective Observational Study of Glomerular Disease.


Journal Article

RATIONALE & OBJECTIVES: Glomerular diseases, including minimal change disease, focal segmental glomerulosclerosis, membranous nephropathy, and immunoglobulin A (IgA) nephropathy, share clinical presentations, yet result from multiple biological mechanisms. Challenges to identifying underlying mechanisms, biomarkers, and new therapies include the rarity of each diagnosis and slow progression, often requiring decades to measure the effectiveness of interventions to prevent end-stage kidney disease (ESKD) or death. STUDY DESIGN: Multicenter prospective cohort study. SETTING & PARTICIPANTS: Cure Glomerulonephropathy (CureGN) will enroll 2,400 children and adults with minimal change disease, focal segmental glomerulosclerosis, membranous nephropathy, or IgA nephropathy (including IgA vasculitis) and a first diagnostic kidney biopsy within 5 years. Patients with ESKD and those with secondary causes of glomerular disease are excluded. EXPOSURES: Clinical data, including medical history, medications, family history, and patient-reported outcomes, are obtained, along with a digital archive of kidney biopsy images and blood and urine specimens at study visits aligned with clinical care 1 to 4 times per year. OUTCOMES: Patients are followed up for changes in estimated glomerular filtration rate, disease activity, ESKD, and death and for nonrenal complications of disease and treatment, including infection, malignancy, cardiovascular, and thromboembolic events. ANALYTICAL APPROACH: The study design supports multiple longitudinal analyses leveraging the diverse data domains of CureGN and its ancillary program. At 2,400 patients and an average of 2 years' initial follow-up, CureGN has 80% power to detect an HR of 1.4 to 1.9 for proteinuria remission and a mean difference of 2.1 to 3.0mL/min/1.73m2 in estimated glomerular filtration rate per year. LIMITATIONS: Current follow-up can only detect large differences in ESKD and death outcomes. CONCLUSIONS: Study infrastructure will support a broad range of scientific approaches to identify mechanistically distinct subgroups, identify accurate biomarkers of disease activity and progression, delineate disease-specific treatment targets, and inform future therapeutic trials. CureGN is expected to be among the largest prospective studies of children and adults with glomerular disease, with a broad goal to lessen disease burden and improve outcomes.

Full Text

Duke Authors

Cited Authors

  • Mariani, LH; Bomback, AS; Canetta, PA; Flessner, MF; Helmuth, M; Hladunewich, MA; Hogan, JJ; Kiryluk, K; Nachman, PH; Nast, CC; Rheault, MN; Rizk, DV; Trachtman, H; Wenderfer, SE; Bowers, C; Hill-Callahan, P; Marasa, M; Poulton, CJ; Revell, A; Vento, S; Barisoni, L; Cattran, D; D'Agati, V; Jennette, JC; Klein, JB; Laurin, L-P; Twombley, K; Falk, RJ; Gharavi, AG; Gillespie, BW; Gipson, DS; Greenbaum, LA; Holzman, LB; Kretzler, M; Robinson, B; Smoyer, WE; Guay-Woodford, LM; CureGN Consortium,

Published Date

  • February 2019

Published In

Volume / Issue

  • 73 / 2

Start / End Page

  • 218 - 229

PubMed ID

  • 30420158

Pubmed Central ID

  • 30420158

Electronic International Standard Serial Number (EISSN)

  • 1523-6838

Digital Object Identifier (DOI)

  • 10.1053/j.ajkd.2018.07.020


  • eng

Conference Location

  • United States